Integrating Carrier Screening Into Reproductive Health Pathways
The growing technological advancement in screening techniques, particularly in next-generation sequencing (NGS) and bioinformatics, has transformed the carrier screening market by improving accuracy, speed, and affordability. Traditional genetic screening tests typically focused on a limited set of conditions, targeting specific populations or high-risk groups. In contrast, modern NGS-based panels screen hundreds of genetic mutations in a single run, providing a much broader and more comprehensive assessment. For instance, in February 2025, F. Hoffmann-La Roche AG (Switzerland) introduced a new category of next-generation sequencing by expansion (SBX) technology, which is playing a vital role in decoding complex diseases like cancer, immune disorders and neurodegenerative conditions. This technology uses high throughput sensor module along with synthetic molecules in order to determine the DNA sequence of a target molecule.